Clinical Practice GuidelinesNeuropathy
Introduction
Detectable sensorimotor polyneuropathy will develop within 10 years of the onset of diabetes in 40% to 50% of people with type 1 or type 2 diabetes (1). Furthermore, up to 50% of children with type 1 diabetes will have subclinical polyneuropathy (2). While clinical neuropathy is uncommon in people with type 1 diabetes within the first 5 years after the onset of diabetes, people with type 2 diabetes may have neuropathy at the time of diagnosis (3). Risk factors for neuropathy include elevated blood glucose levels, elevated triglycerides, high body mass index, smoking and hypertension (4). Foot ulceration, which depends on the degree of foot insensitivity (5), and amputation are important and costly sequelae of diabetic neuropathy (6). Although not all patients with neuropathy have motor or sensory symptoms, the neuropathic pain associated with symptomatic disease is frequently bothersome and often limits physical activity, quality of life and work productivity 7, 8. Additionally, patients with neuropathy utilize more health resources than those without this complication (9). Both somatic and autonomic neuropathies may occur and may require referral to a specialist experienced in managing the affected body system. Mononeuropathy, particularly carpal tunnel syndrome, is common in people with diabetes and can be difficult to diagnose (10). The underdiagnosis of neuropathy is a fundamental problem in the primary care of people with diabetes and impedes the benefits of early identification, the management necessary to achieve improved glycemic control and the prevention of neuropathy-related sequelae (11).
Section snippets
Screening for Peripheral Neuropathy
Screening for neuropathy can be performed rapidly and reliably using the 10-g Semmes-Weinstein monofilament or the 128-Hz tuning fork 12, 13, 14, 15, 16. Methods for using the monofilament or tuning fork to detect diabetic neuropathy are explained in Appendix 8 12, 13, 16. In individuals with significant early progressive symptoms of neuropathy or in whom a clinical suspicion of nondiabetic neuropathy exists, referral for additional neurological evaluation is indicated.
Management of Neuropathy
Intensive glycemic control is effective for the primary prevention and secondary intervention of neuropathy in people with type 1 diabetes 8, 17, 18. In fact, the benefits of intensive insulin treatment persist for over a decade for the primary prevention of neuropathy (19). In those with type 2 diabetes, lower blood glucose levels are associated with a reduced frequency of neuropathy 7, 20. No other disease-modifying treatments are currently available. Multiple treatments are available for the
Other Relevant Guidelines
Targets for Glycemic Control, p. S31
Foot Care, p. S145
Relevant Appendix
References (56)
- et al.
Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial
J Pain
(2005) - et al.
Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial
Pain
(2004) - et al.
Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China
Clin Ther
(2011) - et al.
Duloxetine vs. placebo in patients with painful diabetic neuropathy
Pain
(2005) - et al.
Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study
Pain
(2004) - et al.
The effect of venlafaxine HCl on painful peripheral diabetic neuropathy in patients with type 2 diabetes mellitus
J Diabetes Complicat
(2008) - et al.
Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study
Diabetes Res Clin Pract
(2007) - et al.
Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy
Pain
(1995) - et al.
Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: a prospective double-blind randomized placebo-controlled study
Diabetes Res Clin Pract
(2009) - et al.
The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study
Neurology
(1993)
Comparison of conventional and non-invasive techniques for the early identification of diabetic neuropathy in children and adolescents with type 1 diabetes
Pediatr Diabetes
Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy
Diabetes Care
Vascular risk factors and diabetic neuropathy
N Engl J Med
The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study
Diabetes Care
Lower extremity foot ulcers and amputations in diabetes
Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus
N Engl J Med
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
N Engl J Med
A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost
Pain Med
Carpal tunnel syndrome in patients with diabetic polyneuropathy
Diabetes Care
Underdiagnosis of peripheral neuropathy in type 2 diabetes
Diabetes Care
Does this patient with diabetes have large-fiber peripheral neuropathy?
JAMA
Simple screening tests for peripheral neuropathy in the diabetes clinic
Diabetes Care
Identifying diabetic patients at high risk for lower-extremity amputation in a primary health care setting. A prospective evaluation of simple screening criteria
Diabetes Care
How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures
Diabet Med
Prediction of incident diabetic neuropathy using the monofilament exam: a 4-year prospective study
Diabetes Care
Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years
J Intern Med
The effect of intensive diabetes therapy on the development and progression of neuropathy
Ann Intern Med
Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study
Diabetes Care
Cited by (14)
Effects of hydrotherapy with massage on serum nerve growth factor concentrations and balance in middle aged diabetic neuropathy patients
2020, Complementary Therapies in Clinical PracticeCitation Excerpt :Furthermore, depending on the affected nerves, symptoms of diabetic neuropathy can range from pain and numbness in the legs and feet, to problems with the digestive system, urinary tract, blood vessels, and heart. Although some individuals with diabetic neuropathy have mild symptoms, for other patients, it can be quite painful and disabling [4]. Nerve growth factor (NGF) has a key role in the growth, maintenance, and proliferation of neurons [5].
Agreement between automated and manual quantification of corneal nerve fiber length: Implications for diabetic neuropathy research
2017, Journal of Diabetes and its ComplicationsCitation Excerpt :It can cause pain, imbalance, and foot deformity; in later stages it can result in infection, ulceration, and amputation. In view of a long subclinical phase there is an urgent need for a biomarker of early DSP for use in clinical practice and implementation in future trials of therapies aimed at preventing DSP onset and progression (Canadian Diabetes Association Clinical Practice Guidelines Expert Committee et al., 2013; Ziegler & Luft, 2002). From a research perspective and frequently in clinical practice, the diagnosis of DSP requires confirmation by electrodiagnostic nerve conduction studies (NCS) (England et al., 2005; Tesfaye et al., 2010).
Falls and Balance Impairments in Older Adults with Type 2 Diabetes: Thinking Beyond Diabetic Peripheral Neuropathy
2016, Canadian Journal of DiabetesCitation Excerpt :Allied healthcare professionals (physical and occupational therapists) are trained in detailed evaluations of sensorimotor and cognition domains relevant to postural control, balance and safe mobility. Clinical tools that are reliable and sensitive to detect early changes related to type 2 diabetes in these functions include, but are not limited to, 10 g Semmes-Weinstein monofilament and 128 Hz tuning fork (somatosensory system) (39); Snellen and Pelli-Robson charts (visual system) (40); modified Clinical Test of Sensory Integration for Balance (vestibular system; sensory integration) (17); handheld dynamometer (lower-limb muscle strength) (41); walking performance assessments with cognitive and physical loading (42); and the Trail Making Test Part-B (43) (executive functions). Furthermore, structured exercise interventions have been found to improve balance, reaction times, muscle strength and overall functional status in older adults with type 2 diabetes (44) as well as reducing neuropathic pain and improving sensation in patients with DPN (45).
A review on the prevention and management of diabetes mellitus complications and the role of the pharmacist
2020, SA Pharmaceutical JournalDiagnosis and treatment of the early stages of diabetic polyneuropathy
2020, Meditsinskiy Sovet